BioCentury Hot Topics

BioCentury documents the approval of new modality therapies in a complimentary chart suitable for printing and display, or incorporation into a presentation

With the first wave of GLP-1 therapies poised to become the biggest blockbusters in biopharma history, the focus turns to what's next in obesity, including combination therapies and new mechanisms to address an improved quality and duration of weight loss and co-morbidities

From cross-border deals to start-ups, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. MNCs and Western VCs have been the first to capitalize, sourcing innovation from China at record levels. Now, Western biotechs are embracing the search for deals in Asia. Testing faster in humans is also a recipe for Western and Asia biotechs to de-risk their own compounds, working with China partners. This collection showcases BioCentury's longstanding expertise on the China biotech ecosystem.

Amid growing understanding of the need for greater funding and innovation in women's health, BioCentury is tracking how companies, researchers and investors are improving care for conditions that have been historically overlooked or underserved. Our coverage digs into the science, investment trends, policy shifts and commercial strategies shaping a new era of therapeutics and diagnostics for women’s unique health needs.

From the origins of the orphan drug industry to recent initiatives to expand and accelerate drug development for rare diseases

The Trump administration and Congress are moving quickly to disrupt the federal government. Biopharma leaders need inside information and reliable analyses to navigate the rapidly evolving environment and distinguish between noise and actionable information.